{"name":"Arthritis Innovation Corporation","slug":"arthritis-innovation-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"F14","genericName":"F14","slug":"f14","indication":"Rheumatoid arthritis","status":"marketed"}]}],"pipeline":[{"name":"F14","genericName":"F14","slug":"f14","phase":"marketed","mechanism":"F14 is a humanized monoclonal antibody that targets and inhibits fibroblast growth factor receptor (FGFR) signaling to reduce inflammatory responses in arthritis.","indications":["Rheumatoid arthritis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNNFdFVnROcnUwQWdHWVFCMWotRHR1bWxXUmdSWTBVWVZmdjBkdTlrUFRSUjhKTldpR3B1VkVEQ2dYaExfMkUtMWZyamRrYm5yR1A0NVBTVnJYeWcxWFZZZEw2YkVadmMyMXM3aFM2aERnenUyLVNSNGozcXJJSDRRYldUaHV2Vzg0MWxwekFxYTZ3bkNDRGFJ?oc=5","date":"2026-03-02","type":"pipeline","source":"Contract Pharma","summary":"The 2026 Biologics Wave: Which Innovations Will Break Through? - Contract Pharma","headline":"The 2026 Biologics Wave: Which Innovations Will Break Through?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNZDlpaHhHc2VuaWt2ZHNNYW5ISm1aVFdXX2ZwNEtGcjlCWUJfUVdlcHVZRDN4RUszTjJ1dWlOc3k3QUJVUkQ1OTJsZzBac0dkX2l6dk5rVmh3WDFyTFNoMk9yZnRkSFBiUFJKUWZVRGpkOTZaOHVFM1kzWC1xWXBjREhTQkx5NHVIVlhIRFdFVUxtMmMycUtYYUZR?oc=5","date":"2026-02-07","type":"regulatory","source":"lupin.com","summary":"Lupin receives approval for Leflunomide Tablets USP - Lupin | Press Release - lupin.com","headline":"Lupin receives approval for Leflunomide Tablets USP - Lupin | Press Release","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"GlobeNewswire","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxNdHlrMGk3cUpOQVdncUxTaTRDZnZpdWNLaDBOd2hWNmxMWHp5X1Bjc01fSmRueUc5NjIxUFFVVnBabVE0Wm1uY1JCcWxFWHlvbk1MM1ZRT1kweTQ4RHdia1J1bG4xVDBpZ2lRYXJydXdvS0NqNUFXc2xoUjJDUFdFNGhLOXpsUGNZaHhSY1l3ZnAxQ1JhZDl5WTZuemx0WUJBQzJwM3hXRUt6MzVYU3l2YXR5c3c4dmstSmhNZnkxaDhGZWpUenJyNVFtZE5hWEJpdHhDSHlfUnp3T3VMemthMV9palFuQmtmNFlDR2xRNldaRlhWeUNkeGk5UVI5eEt1WEo2dlJYcHJ4TVhMa2VDMWFaTmR6NmZmRjFsRzIyRjg2b1RPQlNXOVBPSGVGTFNlNl9SblloaThwcnFTanp5UFA5X3JDN3FCWURaSks5N21iUQ?oc=5","date":"2026-01-23","type":"regulatory","source":"Barchart.com","summary":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma, Teijin Pharma, Revolo - ","headline":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQRzFDV25hVEUydWNjSmJXdHlwWDhYX2lkUEp6Zng2d2NDbFZZNS1fLU1aeGRSVzVUU1JiQW5TTk40SE5HQmh0NmxCV2FKQWFVUFR0aWxWVTg3YllJX3M2Z3dOV29TalByaHBoR2RCb3JRcDJrMUZScHdrQld5NjJKU0ZuZU9QTF8tU1o0SVpncTk5VjhQOVE?oc=5","date":"2026-01-11","type":"trial","source":"Yahoo Finance","summary":"Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis - Yahoo Finance","headline":"Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOZTlsUFJjdVV5NDZfTlJ5aHZiZm52bDUxVV8zelNlT2hYdXc5cy1CMV9GbkJZeFZrTk51YXdnUTBmVUJ2THN3TVFnY1g4ajlBdEVIR2dlY0pUeFZvY2VvU3RVaUhvbllVWFJXWE5ocUxYQnFTM0ZfNC1YRTdWQmwtaEx6U3RoWnIySUdfWktOM2owaGJxVHlTWWlVMDFCeW9OMk9USm1wQXE0Ykx0dC1xS2hiOXV1SmhXc2JHRV9zbTJ2QzlhTy1iYk5qT1ktdGYwaXloeTdENVhmRDJuRUN1a09kcnpzOXRMTWJWVWt30gHzAUFVX3lxTE85dGk2RUFHbjZXdGVTRHFkQjE2NktFa2NNM0c5aXM4b2lRdUlYM0NLSGdfZm02S282cG1wUDdOVXRjeERmeDk1OE0zRENwUDQwRWdjbXNwUUduRnRvRVpCNUFMYmNWdnMtS1ZhbE9wS2l0MEc5YzMxZlJkNlRFZmRqdVNUVi1xRmZ4TjNwZmpGcmVkMURHT0drQVlOWDZwM01BVmMzMUp5Y2huaHpQYXRWS0lkcjNndzdWb05EREFWaHZkTjFFUmw5WlotQjdYUlROcGpabVJSRFd2bkh5dWN3WVFqcHpLS1ozR0lKckZMUDkzVQ?oc=5","date":"2025-11-06","type":"earnings","source":"ET Pharma","summary":"Sun Pharma clocks ₹14.4k crore in Q2 FY26 on strong domestic, innovative sales - ET Pharma","headline":"Sun Pharma clocks ₹14.4k crore in Q2 FY26 on strong domestic, innovative sales","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPVjdOV2hFWjVTUFFYVVp2bmotWUlhakxlci1SZGd5RW1qQVBNaF9RR3RiYkJ1Tm8zSGFwMXZTWjVQVmFrR05CcXZSaEdTV3RVOXFPWlplTmlYZHU4Y0ZzNlR6SzN5WDRGWk5VVk12eVpnOUN4Zks2cWdKZksyRUtQbkNkU1R4QQ?oc=5","date":"2025-09-24","type":"trial","source":"Yahoo Finance","summary":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight - Yahoo Finance","headline":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPc2RfdWVyLTZLSENrZE54VUlKMUJ6elBzMU9JYlRnc3VBUHpIbXFtMkxxQVFRdE1BR00tWFhMUW1EWUxxeW5DQWdGVUtoWTR5UnhYTFBtczVKUmtOQXppbTZfSXdDaWFESkFpLVhhNktfbFRqTm5NdEo3OFFWeVktVm9nS2JfbG9rVFNkWDNB?oc=5","date":"2025-07-26","type":"pipeline","source":"Crunchbase","summary":"Arthritis Innovation Corporation - Tech Details - Crunchbase","headline":"Arthritis Innovation Corporation - Tech Details","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPOFpISUVmRloyZnR4c0dVT25yNVUxS2Frc3U3WHc2d3pxUzEtdmtxRDZWb1gyUUphc1pCSERPMHA3TnkyZlBuRmdHWGNScDJ4OFFDaW1rMHQzWjZFSksxZlQ3YjM0QVl2aHA5ZWJBNjdYdHNrZVZMUWxCSlpZYkJBV1JTZ01lMHZvVXQ2dVYtSnZUZ1hJTWtLSzlMOFlBTEJtTGRoTVRZNFRtTG5QckVzbFVKZG1WTXY1NHRuMXNxc09jV0FfRFV6M1llaDVWSEtWSzVvQzNrSXBMQmZHODBkZ1ZYSEtwVHBhQWkxZVJKVmhVTHNWNm5mYUlMdWNqZHNxaFdaUmhJWG82bUI3elM1NjhmZmJ1S2VX?oc=5","date":"2025-06-16","type":"pipeline","source":"prnewswire.com","summary":"Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapies | DelveInsight - prnewswire.com","headline":"Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQQjJCS1pPNUVzTXpOOXdBaFVnY1gwOUhRd1NMY04xZXpRdngzaGt6emVjSHNUa21wSWhCaXBGU0lUZUFFd1BSQnQ3VFlPamkxT3VyS3NDMkJYVmpHWng1UEVOZllFQnZCMU5xLTl3QUFWXzg1SEpyaVlRRWY4VFVUeDUyLUJQSDh5VzJCcWY3MWlFTU0zQ3NUUUMwMDFoVnQ4Q3JmZE1IWXdCVVlBZUlDcC1vT2drMjg?oc=5","date":"2024-05-14","type":"trial","source":"businesswire.com","summary":"Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial - businesswire.com","headline":"Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1FNldPM3pBZlA1S3lEQVNPMGZJTlZIMTZUQkdXdmhiM0g5UV9DTnlkZDQxaUhCcE5mcUE3cE5nNExGVUZ4Szh3VU40SFZFWFUtWXBzdW1lZ0pKcjFDRnk4dlB0N19JajllQmZBNjF2WEwzUk16Q1hsdDAxYzF4dw?oc=5","date":"2023-08-31","type":"trial","source":"Clinical Trials Arena","summary":"AIC concludes patient enrolment in F14 trial to relieve knee surgery pain - Clinical Trials Arena","headline":"AIC concludes patient enrolment in F14 trial to relieve knee surgery pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE55U1lwMU5DbnlQUy1zNDlnV1pibzhmU2lPMDNrakV5eFkzTldFcjBNT21MWl9aNkNsUnA1TnVlV09YaG1Hem93NFFSNFdIR1lpZkQ0OUZlbnkta3VEU05hUm1Hc1NXOEdaOEd1cFRhSXZMMnAxQVV5T1pEU0d1SjA?oc=5","date":"2022-11-08","type":"trial","source":"Labiotech.eu","summary":"MedinCell’s partner AIC registers trial for drug for total knee replacement pain - Labiotech.eu","headline":"MedinCell’s partner AIC registers trial for drug for total knee replacement pain","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}